Key Points
- COO Jeremy Chadwick sold 300 shares at an average price of $90 for a $27,000 transaction (a 0.49% reduction), leaving him with 61,202 shares, according to the SEC filing.
- Quarterly results disappointed: Kymera reported ($0.97) EPS vs. ($0.77) expected and revenue of $2.87M vs. $14.8M expected, reflecting steep year‑over‑year revenue declines and deeply negative margins while the stock trades around $85 with a market cap near $6.9B.
- Mixed catalysts: the FDA granted Fast Track designation to KT‑621 and several analysts raised price targets (consensus ~ $118.90), but a recent pattern of insider selling and the upcoming Q1 webcast on April 30 add near‑term sentiment and event risk.
Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) COO Jeremy Chadwick sold 300 shares of the firm's stock in a transaction dated Wednesday, April 22nd. The shares were sold at an average price of $90.00, for a total transaction of $27,000.00. Following the completion of the sale, the chief operating officer owned 61,202 shares of the company's stock, valued at $5,508,180. The trade was a 0.49% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.
Kymera Therapeutics Trading Down 2.6%
KYMR opened at $84.91 on Friday. The stock has a market capitalization of $6.93 billion, a PE ratio of -23.07 and a beta of 2.28. Kymera Therapeutics, Inc. has a 1-year low of $28.06 and a 1-year high of $103.00. The firm has a 50-day moving average price of $84.63 and a two-hundred day moving average price of $75.50.
Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.97) earnings per share for the quarter, missing the consensus estimate of ($0.77) by ($0.20). The company had revenue of $2.87 million during the quarter, compared to analyst estimates of $14.80 million. Kymera Therapeutics had a negative net margin of 794.04% and a negative return on equity of 28.71%. The company's revenue was down 60.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.88) EPS. On average, research analysts predict that Kymera Therapeutics, Inc. will post -3.65 EPS for the current year.
Institutional Investors Weigh In On Kymera Therapeutics
Several institutional investors have recently modified their holdings of KYMR. Smartleaf Asset Management LLC grew its position in shares of Kymera Therapeutics by 382.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 535 shares of the company's stock worth $42,000 after buying an additional 424 shares during the period. Larson Financial Group LLC grew its position in shares of Kymera Therapeutics by 81.5% during the 3rd quarter. Larson Financial Group LLC now owns 777 shares of the company's stock worth $44,000 after buying an additional 349 shares during the period. Osaic Holdings Inc. grew its position in shares of Kymera Therapeutics by 18,050.0% during the 2nd quarter. Osaic Holdings Inc. now owns 1,089 shares of the company's stock worth $48,000 after buying an additional 1,083 shares during the period. Bessemer Group Inc. grew its position in shares of Kymera Therapeutics by 652.0% during the 3rd quarter. Bessemer Group Inc. now owns 940 shares of the company's stock worth $53,000 after buying an additional 815 shares during the period. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in shares of Kymera Therapeutics during the 4th quarter worth approximately $63,000.
Kymera Therapeutics News Summary
Here are the key news stories impacting Kymera Therapeutics this week:
- Positive Sentiment: FDA granted Fast Track designation to KT‑621 (oral STAT6 degrader) for eosinophilic asthma — accelerates development pathway and can increase regulatory interaction and potential commercial value if clinical data remain positive. FDA Fast Track for KT-621
- Positive Sentiment: Strong analyst and institutional support — multiple recent buy/outperform ratings and a median analyst target near $120, plus large institutional additions reported in recent quarters, provide a bullish backdrop for longer-term upside. Quiver / Analyst & Institutional Snapshot
- Neutral Sentiment: Company will report Q1 2026 results and host a webcast on April 30 — an upcoming earnings call adds near‑term event risk and potential for volatility depending on guidance, cash burn and clinical spend details. Q1 2026 Results Announcement
- Neutral Sentiment: Short interest data reported appears to be a data anomaly (shows 0 shares / NaN change) — not meaningful for positioning until corrected by exchanges/data providers.
- Negative Sentiment: Recent insider sales: COO Jeremy Chadwick sold 300 shares (~$90 each) and Director Bruce Booth executed sales (including a 5,900‑share reduction) — while some trades were under pre‑arranged 10b5‑1 plans, continued insider selling can pressure sentiment. Chadwick Insider Sale Booth Form 4 (10b5-1)
- Negative Sentiment: Broad pattern of insider selling over the past 6 months (many executive sales and relatively few purchases) increases perception of near‑term distribution risk despite institutional buying. Quiver Insider Trading Summary
Wall Street Analysts Forecast Growth
Several research firms have weighed in on KYMR. Citigroup raised their price objective on shares of Kymera Therapeutics from $110.00 to $120.00 and gave the company a "buy" rating in a research report on Monday, March 2nd. Piper Sandler raised their price objective on shares of Kymera Therapeutics from $125.00 to $140.00 and gave the company an "overweight" rating in a research report on Thursday, February 26th. Stephens lifted their price target on shares of Kymera Therapeutics from $95.00 to $100.00 and gave the stock an "overweight" rating in a research report on Monday, March 2nd. Weiss Ratings reiterated a "sell (d-)" rating on shares of Kymera Therapeutics in a research report on Tuesday. Finally, BTIG Research lowered their price target on shares of Kymera Therapeutics from $138.00 to $134.00 and set a "buy" rating for the company in a research report on Thursday, February 26th. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $118.90.
View Our Latest Stock Report on KYMR
Kymera Therapeutics Company Profile
(
Get Free Report)
Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company's proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.
The company's pipeline emphasizes immunology and oncology.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
